Class Action Filed Against Altimmune, Inc. – Investors with Losses Encouraged to Contact Johnson Fistel

Core Viewpoint - A class action lawsuit has been filed against Altimmune, Inc. on behalf of investors who purchased its securities during the specified class period, following disappointing trial results that led to a significant drop in stock price [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Johnson Fistel, PLLP, representing investors who bought Altimmune securities between August 10, 2023, and June 25, 2025 [1]. - Investors wishing to act as lead plaintiffs must file their motion by October 6, 2025 [1][2]. Group 2: Trial Results and Stock Impact - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, which failed to achieve statistical significance in its primary endpoint of fibrosis reduction [3]. - The stock price of Altimmune plummeted from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in just one day [3].